Parvalbumin inhibitory interneurons (PVIs) are crucial for maintaining proper excitatory/inhibitory balance and high-frequency neuronal synchronization. Their activity supports critical developmental trajectories, sensory and cognitive processing, and social behavior. Despite heterogeneity in the etiology across schizophrenia and autism spectrum disorder, PVI circuits are altered in these psychiatric disorders. Identifying mechanism(s) underlying PVI deficits is essential to establish treatments targeting in particular cognition. On the basis of published and new data, we propose oxidative stress as a common pathological mechanism leading to PVI impairment in schizophrenia and some forms of autism. A series of animal models carrying genetic and/or environmental risks relevant to diverse etiological aspects of these disorders show PVI deficits to be all accompanied by oxidative stress in the anterior cingulate cortex. Specifically, oxidative stress is negatively correlated with the integrity of PVIs and the extracellular perineuronal net enwrapping these interneurons. Oxidative stress may result from dysregulation of systems typically affected in schizophrenia, including glutamatergic, dopaminergic, immune and antioxidant signaling. As convergent end point, redox dysregulation has successfully been targeted to protect PVIs with antioxidants/redox regulators across several animal models. This opens up new perspectives for the use of antioxidant treatments to be applied to at-risk individuals, in close temporal proximity to environmental impacts known to induce oxidative stress.

Molecular Psychiatry (2017) 22, 936–943; doi:10.1038/mp.2017.47; published online 21 March 2017

Proper cortical excitatory-inhibitory balance through GABAergic circuits is critical for supporting cognitive, affective and social functions.1,2 Some of these inhibitory circuits are impacted in psychiatric disorders (for example, autism,3 schizophrenia and4 bipolar disorder5). In particular, alterations in parvalbumin-expressing interneurons (PVIs) are highly replicated findings in postmortem brains of schizophrenia patients,67 and are reported in bipolar (BP)6 and autism spectrum disorders (ASD).8 Anomalies in PVIs therefore constitute a pathological hallmark common to several different psychiatric conditions. Elucidating mechanisms underlying the causes and consequences of these alterations may help to identify biomarkers and novel targets for the improved detection, prevention and treatment. Here, we review published data and present novel results which provide compelling evidence for the convergence of various genetic and environmental risk factors onto oxidative stress leading to PVI impairment. We propose this represents a ‘common pathological pathway’, which contributes to schizophrenia, and at least some forms of ASD.

ABERRANT PVI CIRCUITS IN PSYCHIATRIC DISORDERS

PVIs, which express parvalbumin (a high-affinity calcium-binding protein), are fast-spiking, non-adapting interneurons. Because their inhibitory terminals synapse onto the cell body and axon initial segment of their target neurons, PVIs control the output of postsynaptic neurons via feedforward and feedback inhibition. They coordinate the activity of neuronal assemblies, particularly in high-frequency synchrony.1 PVI-associated circuits shape the processing and flow of information required for sensory perception, working memory, attention, learning, memory and social behavior. They also drive the early refinement of cortical networks. Maturation of PVIs and their specialized extracellular matrix (the perineuronal net, PNN) enveloping most PVIs9 define critical periods of network plasticity during postnatal development.10 There is accumulating evidence for anomalies of PVI-associated circuits in schizophrenia, but also in BP and ASD. In schizophrenia, these alterations include reduced expression of parvalbumin, GAD67 (GABA synthesizing enzyme), Kv3.1-containing K+–channels, changes in their pre- and postsynaptic terminals,12,13 and abnormal PNN13 known to promote interneuron maturation, synaptic/network stability14,15 and protection against oxidative stress.16 Together with an immature developmental gene expression profile of PVIs in ASD and schizophrenia,17 this suggests a defect in the proper maturation of these interneurons. Dysfunction of PVI-associated networks may lead to impaired high-frequency neuronal synchrony,18 and contribute to altered cognitive and behavioral abnormalities.

1Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly-Lausanne, Switzerland; 2Laboratory for Psychiatric and Molecular Neuroscience, Harvard Medical School, McLean Hospital, Belmont, MA, USA; 3Synaptic transmission H. Lundbeck A/S, Valby, Denmark; 4Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, USA; 5Center for Brain Science, Department of Molecular Cellular Biology, Harvard University, Cambridge, MA, USA; 6F M Kirby Neurobiology Center, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; 7George Washington Institute for Neuroscience, The George Washington University, Washington, DC, USA; 8F. Hoffmann-La Roche, Roche Pharmaceutical and Early Development, Neuroscience, Ophthalmology & Rare Disease (NORD) DTA, Discovery Neuroscience, Roche Innovation Center Basel, Basel, Switzerland; 9Institute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland; 10Department of Psychiatry, Neuroscience, and Ophthalmology, Friedman Brain Institute, Mindaq Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, NY, USA and 11Neuroscience and Pain Research Unit, BioTherapeutics Research and Development, Pfizer, Cambridge, MA, USA. Correspondence: Professor KQ Do, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly-Lausanne CH-1008, Switzerland.
E-mail: kim.do@chuv.ch
12Co-first authors.
Received 3 August 2016; revised 21 December 2016; accepted 17 January 2017; published online 21 March 2017
Figure 1. Relationship between oxidative stress and PVI integrity in the ACC of 2–3 month-old animal models relevant to schizophrenia, autism and/or redox dysregulation. (a) Oxidative stress (assessed by the immunoreactivity intensity against 8-oxo-2'-deoxyguanosine (8-oxo-dG), a marker of mitochondrial DNA oxidation), number of PV-IR cells (PV cells) and number of PV cells enwrapped with a WFA-labeled PNN. # indicates models for which the presented data are already published elsewhere.39,41 The references indexed below provide detailed descriptions of each investigated model and its control. 22q11: mice with a 22q11.2 deletion (LgDel/+)(n = 7 animals per group); 15q13.3: mice with a 15q13.3 deletion (Df[h15q13.3]/+)(n = 5, 7); 1q21: mice with a 1q21 deletion (Df[h1q21]/+)(from M Didriksen)(n = 4 per group), SRR: serine racemase KO mice(n = 5, 7); FMR1: FMR1 KO mice(n = 7, 8); PV-GCLC: mice with conditional KO of GCLC (catalytic subunit of the key synthesizing enzyme of GSH) in PVIs(n = 5 per group); GRIN2A: GRIN2A KO mice(n = 7 per group); GCLM: GCLM KO mice(n = 5 per group); GCLM GBR: GCLM KO mice treated with dopamine uptake inhibitor GBR12909 during postnatal development (P10-20)(n = 5 per group); GRIN2A GBR: GRIN2A KO mice treated with GBR12909 during postnatal development (P10-20)(n = 7 per group); ODS BSO: ODS rats treated with the specific inhibitor of GSH synthesis (BSO) during postnatal development (P5-16)(n = 4 per group); NVHL: rats with a neonatal ventral hippocampal lesion(n = 6, 7); MAM: rats treated on gestation day GD17 with MAM(n = 4, 6); Poly(I:C): mice with a sub-threshold prenatal immune challenge (on GD9) with poly(I:C); +Str: poly(I:C)-treated mice stressed at preadolescence (P30-40)(n = 5 per group). Data are depicted by the mean ± s.d. (in red: animal models; in blue: their respective controls). *** P < 0.001; ** P < 0.01, * P < 0.05. (b) Quantile density contours with linear regression (red) and smoothing spline (green) plots illustrating the relationships between changes in oxidative stress (8-oxo-dG-IR), in number of PV cells, and in number of PV cells with WFA-labeled PNN (PV cells+PNN) for all animal models relative to their respective controls (JMP11, SAS Institute, Cary, NC, USA). (c) As in (b) but illustrating the relationship between changes in number of PV cells+PNN and in number of PV cells for all animal models relative to their respective controls. Brief method description: perfused fixed brains from all animal models were sent to Lausanne where immunohistological preparation, image acquisition and analyses were performed blindly using the methods described previously.39 Three to four sections per animal were used for the analyses. Analyses of 8-oxo-dG-IR intensity, numbers of PV-IR cells and PV-IR cells surrounded with a WFA-labeled PNN were done in a region of interest comprising all layers of the ACC. Oxidative stress was assessed in all cells of ROI. Each animal model was compared with its own control animals. Only males were analyzed, except for the GRIN2A model where individuals from both sexes were used. On the basis of previously analyzed data,39 sample size was chosen to detect ~ 25% change in number of PV-IR cells and ~ 75% change in 8-oxo-dG intensity with a power of 80% at a significant α-value set to P = 0.05. Statistical significance was tested by comparing means of the different models with their respective controls using the Dunnett’s test. When variances were not equal, we used the Welch’s test to give confidence and confirm the Dunnett’s test outcome. ACC, anterior cingulate cortex; BSO, buthionine sulfoximine; KO, knockout; MAM, methylazoxymethanol acetate; NVHL, neonatal ventral hippocampal lesion; ODS, osteogenic disorder Shionogi; PNN, perineuronal net; PV, parvalbumin; PV-IR, parvalbumin-immunoreactive; PVI, parvalbumin inhibitory interneuron; WFA, Wisteria floribunda agglutinin.
sensory perception, social and cognitive deficits found in patients. Understanding the mechanism(s) driving PVI anomalies is therefore central to the development of novel therapeutic strategies, targeting in particular negative symptoms and cognition.

**PVIS ARE AFFECTED BY MANY GENETIC AND ENVIRONMENTAL RISK FACTORS OF NEURODEVELOPMENTAL DISORDERS**

Schizophrenia and ASD are disorders with heterogeneous etiologies, involving a large array of genetic and environmental vulnerabilities. In preclinical models, environmental risk factors (for example, prenatal maternal stress, immune challenge, hypoxia, early-life iron deficiency, maternal separation and social isolation) and manipulations of genes associated with these diseases (for example, DISC1, DTNB1, ERBB4, NRG1, SHANK3 and CNTAP2) affect PVIs. Because of their positioning within cortical networks, their activity-dependent maturation and the plasticity of their associated networks, PVIs might be highly sensitive to abnormal cortical organization. Changes in expression of parvalbumin, GAD67, or GABA receptors may thus reflect homeostatic adaptations to alterations of neuronal wiring caused by diverse independent mechanisms of genetic and/or environmental origins. Alternatively, PVI alterations induced by a large variety of genetic and environmental factors may be attributed to a single or a subset of pathological mechanism(s) common to all these conditions. For example, PVI dysfunction in prefrontal cortex could be secondary to reduced glutamatergic transmission.

Another potential mechanism could be oxidative stress, for which there is considerable evidence in schizophrenia, BP and ASD. Novel in vivo NAD+/NADH 31P-MRS technique has confirmed redox dysregulation in schizophrenia patients. Indeed, PVIs are vulnerable to redox dysregulation/oxidative stress. To examine the hypothesis that oxidative stress is part of a common pathway leading to PVI abnormalities, we performed a comparative immunohistological analysis of oxidative stress and PVIs in the anterior cingulate cortex (ACC) of a panel of genetic and/or environmental models relevant to schizophrenia and ASD. Oxidative stress was detected with an antibody against 8-oxo-2'-deoxyguanosine (8-oxo-dG), a marker for DNA oxidation. PVI integrity was assessed with an antibody against parvalbumin and with the lectin, *Wisteria floribunda agglutinin* (WFA), to label the PNN (for brief methods, see legend of Figure 1). Models included genetically engineered mice-bearing human copy number variations linked to increased risk for schizophrenia and/or ASD (deletion in the 22q11, 15q13 or 1q21 loci) or knockout (KO) for genes associated with these disorders (FMR1, serine racemase (SRR) and GRIN2A), rodents with deficient glutathione (GSH) synthesis (GCLM KO mice, mice with conditional GCLC KO in PVIs, rats with transient GSH depletion during development), mouse models of gene-environment interactions (early postnatal oxidative challenge in GCLM and GRIN2A KO mice), an environmental ‘two-hit’ mouse model of schizophrenia (maternal immune challenge+periparturial stress), and neurodevelopmental rat models relevant to schizophrenia (neonatal ventral hippocampal lesion (NVHL) and methylazoxymethanol acetate (MAM)). All analyses were performed in late adolescent/young adult animals (2–3 months old), and the results are summarized below and in Figure 1.

**OXIDATIVE STRESS AND PVI INTEGRITY IN PRECLINICAL MODELS OF GENETIC AND ENVIRONMENTAL RISKS**

Mice with the human 22q11.2 deletion (LgDel/+) The 22q11.2 deletion represents the most common microdeletion, and causes craniofacial, cardiovascular abnormalities, immunodeficiency and cognitive dysfunctions. Microdeletion of this region accounts for ~0.3% of persons diagnosed with schizophrenia, and leads to structure and connectivity abnormalities in various brain regions including the cortex, hippocampus, and cerebellum. Mice modeling the human 22q11.2 deletion show cognitive deficits, impaired sensorimotor gating and fear conditioning. In addition, they have disrupted cortical neurogenesis, abnormal interneuron migration/placement, reduced density of parvalbumin-immunoreactive (PV-IR) synapses and abnormal formation of excitatory synapses. Our analysis shows that, relative to their control wild-type (WT) mice, adult LgDel/+ mice displayed higher oxidative stress (+125% 8-oxo-dG immunoreactivity intensity), decreased number of PV-IR cells (~22%), and PV-IR cells surrounded by WFA-labeled PNN (~38%).

Mice with the human 15q13.3 deletion (Df[h15q13]/+) Deletion or duplication of the chromosome region, 15q11-13, cause severe neurological phenotypes. The 15q13.3 deletion confers high risk for schizophrenia, but also epileptic seizures, attention deficit, aggression, developmental delay and ASD. Mice with such microdeletion (Df[h15q13]/+) display several features resembling the clinical syndromes, including changes in schizophrenia relevant domains like reduced evoked gamma oscillations and seizure susceptibility. Relative to their control mice, adult Df[h15q13]/+ mice showed increased oxidative stress (+262% 8-oxo-dG immunolabeling intensity), lower number of PV-IR cells (~35%) and PV-IR cells enwrapped with PNN (~45%).

Mice with the human 1q21 deletion (Df[h1q21]/+) The symptoms caused by a 1q21.1 microdeletion overlap with those seen in individuals with a 22q11.2 microdeletion. These include congenital heart defect, facial abnormalities, developmental delay, microcephaly and neuropsychiatric disorders, including schizophrenia. Compared to their control mice, adult Df[h1q21]/+ mice, whose full phenotyping is ongoing, did not show any significant oxidative stress, deficit in PV-IR cells and in WFA-labeled PNN.

**FMR1 KO mice** The Fragile X syndrome results from the expansion of an unstable trinucleotide repeat, hypermethylation and transcriptional shutdown of the fragile X mental retardation 1 (FMR1) gene causing the lack of the FMR1 protein. Fragile X syndrome patients present a complex neuropsychiatric phenotype. Half of the patients meet the diagnostic criteria for ASD; many present anxiety, attention deficit, cognitive impairment and preservative behaviors. Rare mutations in the FRM1 gene are also associated with schizophrenia. FMR1 KO mice have phenotypes that resemble the human disorder and display abnormalities in GABAergic circuits including reduced PV-IR cell density. In adult FMR1 KO mice, we observed a strong increase in oxidative stress (+307% 8-oxo-dG immunolabeling intensity relative to their control WT mice) together with a decreased number of PV-IR cells (~48%), and PV-IR cells surrounded by WFA-labeled PNN (~50%).

**SRR KO mice** Genetic and biochemical findings suggest that SRR, the enzyme that converts L-serine to D-serine, and D-serine itself are reduced in schizophrenia. Low levels of D-serine, the dominant endogenous co-agonist of NMDA receptors (NMDAR) in forebrain, may cause NMDAR hypofunction as observed in SRR KO mice. Although a previous study reported no alteration of parvalbumin immunoreactivity in hippocampus, pre- and infralimbic cortices of SRR KO mice, our analysis revealed reduced number of PV-IR cells (~26% relative to their control WT mice) and PV-IR cells surrounded by PNN (~35%) in the ACC of adult SRR KO mice. This was accompanied by an increase in intensity of 8-oxo-dG immunoreactivity (~410%).
GRIN2A KO mice
A large genome-wide association study identified independent loci associated with schizophrenia that contain numerous brain-enriched genes involved in glutamatergic transmission, including GRIN2A coding for the NMDAR subunit NR2A. Mutations in GRIN2A gene have been identified in intellectual disabilities, epilepsy, ASD and schizophrenia. GRIN2A KO mice show learning deficits and altered emotional-like behaviors. Relative to their control WT mice, GRIN2A KO mice display neither significant oxidative stress nor PV-IR deficit. The number of PV-IR cells with PNN was however slightly reduced in KO mice (~11% relative to their control WT). However, when an additional oxidative challenge was applied during early postnatal development (from days 10 to 20), young adult GRIN2A KO mice showed significant oxidative stress (+159% relative to WT), reduced number of PV-IR cells (~17%) and PV-IR cells surrounded by WFA-labeled PNN (~36%). The oxidative insult consisted of 10-days administration of GBR12909 (GBR), a dopamine uptake inhibitor, leading to elevated extracellular dopamine levels and subsequent generation of reactive oxygen species (ROS) and reactive compounds. This treatment mimics to some extent dopamine release induced by environmental stress. Such GBR treatment did not have any significant effects however in WT mice. These findings indicate that an exogenous stress during development induces long-lasting oxidative stress along with PVI/PNN deficits in GRIN2A KO mice.

GCLM KO mice and other models of GSH deficiency
Altered levels of enzymatic and non-enzymatic antioxidants, including decrease in GSH, are reported in blood or brain of some patients suffering from schizophrenia, BP or ASD. Polymorphisms and copy number variations in genes related to the GSH synthesis and metabolism are associated with schizophrenia. Moreover, subjects with high-risk genotype of the key GSH synthesizing gene GCLC presents low prefrontal GSH levels. Mice with a functional deletion of the modulatory subunit (GCLM) of the key GSH synthesizing enzyme constitute a model of redox dysregulation with increased oxidative stress and PVI/PNN deficits. These mice display neurochemical, and behavioral anomalies relevant to schizophrenia and BP. Relative to their control WT, young adult GCLM KO mice showed oxidative stress (+53% 8-oxo-dG immunolabeling intensity), but no PV/PNN deficit. However, an early-life GBR-induced oxidative insult (from days 10 to 20) led to a further increase of 8-oxo-dG immunolabeling (+127% relative to WT mice), along with a decreased number of PV-IR cells (~44%) and PV-IR cells surrounded by PNN (~52%) in young adult GCLM KO mice, compared with WT controls. In osteogenic disorder Shionogi rats lacking the capacity for ascorbic acid synthesis, a transient GSH depletion induced pharmacologically with the specific inhibitor of GSH synthesis (BSO) during the postnatal period of PVI maturation (P5-P16) also sufficed to decrease the number of PV-IR cells (~13% relative to control rats) and to increase 8-oxo-dG immunolabeling (+77%) in the ACC of adult animals. Finally, a genetically induced blockade of GSH synthesis restricted to PVIs (PV/GCLC KO mice) also led to reduced number of PV-IR cells (~26% relative to their control mice) and PV-IR cells surrounded by WFA-labeled PNN (~36%) in the ACC. Together, this demonstrates that a GSH deficiency confers a vulnerability to oxidative stress-induced PVI impairment.

Environmental 'two-hit' mouse model
Prenatal infection and exposure to traumatizing experiences during peripuberty have been associated with increased risk for neuropsychiatric disorders. Prenatal infection and psychological trauma in peripubertal life can also synergistically increase the risk for schizophrenia. Combining a sub-threshold prenatal immune challenge (at embryonic day E9) using the viral mimetic, poly(I:C) with sub-chronic unpredictable stress during pubescence (post-natal days 30–40) causes synergistic effects on adult mouse behaviors, neurochemistry and number of hippocampal PV-IR cells. Here, it was found that the two environmental hits synergistically affected the oxidative stress (+190%), the number of PV-IR cells (~38%) and PV-IR cells enwrapped with WFA-labeled PNN (~63%) in the ACC of adult poly(I:C)/stressed relative to their naive control mice.

NVHL rat model
Developmental manipulations and insults inducing adult deficits in rodents provide an opportunity to explore mechanisms involved in a delayed emergence of anomalies driven by developmental alterations. A widely used tool to assess developmental trajectories of adult-onset prefrontal cortical deficit is the NVHL. This procedure yields adult animals with PFC-dependent neurological, electro-physiological and behavioral anomalies related to schizophrenia phenotypes, all of which emerge during adolescence. In young adult NVHL rats, there was a strong increase of 8-oxo-dG immunolabeling intensity (+450% relative to control sham rats) accompanied by a decrease in number of PV-IR cells (~43%) and PV-IR cells surrounded by PNN (~55%) in the ACC.

MAM developmental rat model
Dopamine dysfunction has been regarded as the primary factor underlying psychosis. Administration in rats of the DNA-alkylating agent MAM at gestational day 17 affects hippocampal-midbrain-striatal circuits, causing an elevated subcortical dopamine function through changes in descending outputs from the medial temporal lobe. The MAM rat model incorporates the disruption of brain development, believed to be fundamental to psychotic disorders. Prenatal administration of MAM recapitulates a neurodevelopmental disruption leading to histological, neurophysiological, and behavioral deficits analogous to schizophrenia. This includes reduction of PV-IR cells within the medial prefrontal cortex and ventral hippocampus. Our analysis of the ACC revealed an increase of 8-oxo-dG immunolabeling intensity (+164%) in MAM relative to their control rats. In parallel, the number of PV-IR cells and PV-IR cells surrounded by WFA-labeled PNN were decreased (~44% and ~49%, respectively).

IS OXIDATIVE STRESS CAUSAL TO PVI IMPAIRMENTS?
Overall, our analysis remarkably showed that PVI deficit in the ACC was in all cases accompanied by oxidative stress. By contrast, significant oxidative stress and PVI deficit were absent in the 1q21 deletion model and GRIN2A KO mice. Young adult GCLM KO mice showed no PVI/PNN deficit despite small signs of oxidative stress. However, both GRIN2A and GCLM KO mice were susceptible to early postnatal oxidative challenge induced by GBR (from P10 to P20) as evidenced by a long-lasting increase in oxidative stress and PVI/PNN deficits. Considering all investigated animal models, increased oxidative stress correlated negatively with the relative decreased number of PV-IR cells or PV-IR cells with PNN (Figure 1b), suggesting a direct link between oxidative stress and PVI anomalies. Furthermore, there was a strong relationship between the decreases in number of PV-IR cells and number of PV-IR cells with PNN (Figure 1c), indicating that both reduction of PV immunoreactivity and weakening of PNN are coupled, thus reinforcing their relation to oxidative stress. The association between oxidative stress and PVI deficit in the medial prefrontal cortex has been also observed in other models not reported here: rodents treated with NMDAR antagonists, isolated mice bearing a deletion of the NMDAR subunit NR1 in forebrain interneurons, isolated rats, socially defeated rats, mutant DISC1 mice (Figure 2). Although we have focused on

Oxidative stress in PVI as mechanism in SZ models
P Steullet et al

Molecular Psychiatry (2017), 936–943
A causal effect of oxidative stress on PVI integrity or phenotype is strongly supported by the fact that oxidative stress precedes PVI deficit in the hippocampus and by the protective effect of antioxidants on PVis in several models (GRB-treated GCLM mice, ketamine-treated mice, isolated rat, isolated mice with deletion of NR1 in forebrain interneurons, social defeated rats and NVHL rats). Many early-life stressors relevant to environmental risk factors for schizophrenia (maternal separation, hypoxia and early-life iron deficiency) also lead to PVI deficit in medial prefrontal cortex and/or hippocampus of rodents (Figure 2). Although the link between PVI deficit and oxidative stress has not been investigated in the above studies, it is a reasonable hypothesis that oxidative stress contributes to prefrontal and hippocampal PVI deficit induced by these environmental insults known to generate oxidative stress and neuroinflammation.

As fast-spiking neurons, PVIs contain many mitochondria to meet their high-energy demand. Therefore, they are vulnerable to weakened antioxidant defenses, excessive production of ROS and diminished mitochondrial support. However, PVIs are also particularly susceptible to redox dysregulation/oxidative stress during their postnatal maturation when their fast-spiking properties are not yet fully developed and the formation of the protective PNN enwrapping them are not yet complete. Based on the fact that a sub-threshold immune challenge primes microglia to be activated at pre-pubertal stress resulting in ROS production and PVI/PNN deficits. Excess dopamine also generates ROS, which may not be efficiently neutralized when the antioxidant defenses are suboptimal as in GCLM and GRIN2A KO mice. Thus, NMDAR hypofunction causes a susceptibility to oxidative stress. This could be due to the neuronal production of IL-6 mediating NADPH oxidase activation and/or the weakening of the antioxidant capacities. This might explain the effects observed in SRR and GRIN2A KO mice (Figure 2). Furthermore, phencyclidine administration results in hypermethylation of CpG sites in the promoter of PV gene which includes binding sites for Nrf2, the master regulator of antioxidant defense. This may also contribute to oxidative damage and PVI/PNN deficits. Concerning the environmental ‘two-hit’ model, we propose that a sub-threshold immune challenge primes microglia to be activated at pre-pubertal stress resulting in ROS production and PVI/PNN deficits. Excess dopamine also generates ROS, which may not be efficiently neutralized when the antioxidant defenses are suboptimal as in GCLM and GRIN2A KO mice. Thus, a central role for oxidative stress is compatible with glutamatergic and dopaminergic dysregulations, as well as neuroinflammatory processes. The mechanisms by which oxidative stress and PVI deficits occur in several models that we analyzed (copy number variations mouse models, FMR1 KO mice, and hypoxia) suggest that oxidative stress interferes with the normal development of PVIs and conflicts with the protection mechanisms to achieve normal fast-spiking properties during their postnatal maturation when their fast-spiking properties are not yet fully developed and the formation of the protective PNN enwrapping them are not yet complete.

It is remarkable that oxidative stress is observed in so many models of genetic and environmental risks for psychiatric diseases. It is unlikely however that the mechanisms causing oxidative stress are similar in all models. Oxidative stress could be a consequence of perturbations within a number of systems known to be disrupted in these disorders, that is, glutamatergic, neuroimmune, dopaminergic, antioxidant and mitochondrial systems. Thus, NMDAR hypofunction causes a susceptibility to oxidative stress. This could be due to the neuronal production of IL-6 mediating NADPH oxidase activation and/or the weakening of the antioxidant capacities. This might explain the effects observed in SRR and GRIN2A KO mice (Figure 2). Furthermore, phencyclidine administration results in hypermethylation of CpG sites in the promoter of PV gene which includes binding sites for Nrf2, the master regulator of antioxidant defense. This may also contribute to oxidative damage and PVI/PNN deficits. Concerning the environmental ‘two-hit’ model, we propose that a sub-threshold immune challenge primes microglia to be activated at pre-pubertal stress resulting in ROS production and PVI/PNN deficits. Excess dopamine also generates ROS, which may not be efficiently neutralized when the antioxidant defenses are suboptimal as in GCLM and GRIN2A KO mice. Thus, a central role for oxidative stress is compatible with glutamatergic and dopaminergic dysregulations, as well as neuroinflammatory processes. The mechanisms by which oxidative stress and PVI deficits occur in several models that we analyzed (copy number variations mouse models, FMR1 KO mice, and hypoxia) suggest that oxidative stress interferes with the normal development of PVIs and conflicts with the protection mechanisms to achieve normal fast-spiking properties during their postnatal maturation when their fast-spiking properties are not yet fully developed and the formation of the protective PNN enwrapping them are not yet complete.
MAM and NVHL rat models) remain, however elusive, but may involve dysregulation within the systems mentioned above. Interestingly, the 22q11 locus contains the gene encoding COMT (a dopamine degrading enzyme) and six genes for proteins expressed in mitochondria,107 among which at least two (PRODH, and TRXR2) are implicated in the defense against oxidative stress.108 Likewise, MAM is known to decrease brain GSH levels.109

Our hypothesis that abnormal PVI-associated networks in schizophrenia and ASD has a neurodevelopmental origin and implicates redox dysregulation/oxidative stress should be however further tested in other models. For instance, mice with a deletion of α7-nAChR, whose expression and function are affected in schizophrenia,110 display reduced expression of parvalbumin, GAD67, and NMDAR in PVI.94 In this model, oxidative stress might also be the mechanism responsible for the PVI deficit, as activation of α7-nAChR inhibits NF-kB-dependent pathways and mediates Nrf2-induced antioxidant responses, supporting an anti-inflammatory and neuroprotection role for this nicotinic receptor.95 Interestingly, the gene CHRNA7 coding for this receptor is located within the 15q13.3 loci and may contribute to the neuropsychiatric phenotype caused by a microdeletion of this chromosomal region.111

Likewise, impaired PVI in mutant mice with reduced dysbindin-1 [ref. 25] could result from oxidative stress as dysbindin interacts with the antioxidant enzymes peroxiredoxins 1 and 2.96 The neuregulin-1/ErbB4-mediated pathway, whose involvement in the etiology of schizophrenia is strongly suspected, is also required for migration and appropriate wiring of PVIs in the postnatal cortex.26 Postnatal conditional KO of ERBB4 on PVI leads to reduced glutamatergic drive and tends to diminish NMDAR function in these interneurons.96 Involvement of redox dysregulation/oxidative stress in the PVI anomalies mediated by the disruption of neuregulin-1/ErbB4 signaling remains speculative, although this cascade has been implicated in neuroprotection against oxidative stress112 and in stimulation of antioxidant defense.27

In contrast, aberrant migration of interneuron precursors and perturbed positioning of PVI within the cortical circuits due to genetic and/or prenatal environmental factors may be mediated by mechanisms independent of oxidative stress. Manipulations of other genes associated with intellectual disability and ASD (for example, MEC2P, NLGN3, Shank3; CNTNAP2) reveal diverse abnormalities within cortical GABAergic circuits.79–81,135 Both increase and decrease in number of PV-IR cells are reported. Moreover, Shank1 and Shank3 KO mice show a reduced number of PV-IR cells but no deficit in WFA-labeled PNN in the somatosensory cortex.27 In contrast to the schizophrenia models, this suggests no convergent mechanism responsible for PVI anomalies in ASD relevant models.

CONCLUSION

Redox dysregulation/oxidative stress is a common pathological mechanism affecting prefrontal PVI during postnatal maturation in a strikingly diversified number of models relevant to schizophrenia and some forms of ASD. Although our analysis focused on oxidative stress-induced PVI deficit in the prefrontal cortex, this deficit may also hold for other brain regions like the hippocampus, as shown in some models of schizophrenia (for example, GCLM KO, ketamine, MAM, polyIC and social defeat).12,22,37,47,48,84 This confluence suggests that oxidative stress could be the main agent responsible for PVI-associated network anomalies particularly in schizophrenia. The fact that peri-adolescent administration of antioxidants can restore or protect PVI integrity in some animal models provides a strong support that early antioxidant-based treatments might be beneficial to PVI-associated networks. Knowing the role of PVI in cognition and social behavior, this could improve cognitive processing and ameliorate general functioning of patients. Such preventive intervention will require however the identification of reliable biomarkers for brain oxidative stress/redox dysregulation and PVI function in high-risk individuals.

CONFLICT OF INTEREST

MD is employed by Lundbeck A/S, LS is employed by F. Hoffmann-La Roche and PD is employed by Pfizer. J-HC received funding from Hoffmann-La Roche to cover material, technical costs and confocal microscopy fees for the Fmr1 KO study. The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank Dr Sandra Giovanioli, Dr Aubin Michalon, Dr Kraftsk, Ms Adeline Cottier for excellent technical assistance and Dr Fulvio Magara and the technical staff of the Centre d’Études du Comportement, Center for Psychiatric Neuroscience, CHUV, for their support in animal facilities. We thank our financial supports: Swiss National Science Foundation (# 31-116689 to KQD and # 310030_135736/1 to KQD and PS), National Center of Competence in Research (NCCR) "SYNAPSY - The Synaptic Bases of Mental Diseases" from the Swiss National Science Foundation (no 51AU00_125759 to KQD), the NHM Silvio Conte Center (PS09MH094271) (to TKH), the Banque Lombard Odier & Cie SA and the Avina, Damm-Etienne, Pro Scientia et Arte and Alamyra Foundations. Roche covered materials, technical costs and confocal microscopy platform fees for the analysis of the Fmr1 KO study. Experiments were approved by the local ethical and veterinary committees for each collaborator who provided us with their animal models.

REFERENCES

1. Hu H, Gan J, Jonas P. Interneurons. Fast-spiking parvalbumin(+)-GABAergic interneurons from cellular design to microcircuit function. Science 2014; 345: 1255263.
2. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O’Shea DJ et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011; 477: 171–178.
3. Zikopoulos B, Babas H. Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neurosci 2013; 7: 609.
4. Inan M, Petros TJ, Anderson SA. Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia. Neurobiol Dis 2013; 53: 36–48.
5. Savitz JB, Price JL, Drevets WC. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network. Neurosci Biobehav Rev 2014; 42: 132–147.
6. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of patients with schizophrenia. Schizophren Res 1997; 24: 349–355.
7. Lencz T, Cusack F, Curley AA, Glasier JT, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012; 35: 57–67.
8. Sakai T, Oshima A, Nozaki Y, Ida I, Haga C, Akiyama H et al. Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychology 2008; 28: 143–150.
9. Hashemi E, Anzà J, Rogers H, Noctor SC, Martinez-Cerdeno V. The number of parvalbumin-expressing interneurons is decreased in the medial prefrontal cortex in autism. Cereb Cortex 2016. pii:bhw021.
10. Rossier J, Bernard A, Cubangchal JH, Perrenoud Q, Savoye A, Gallopin T et al. Cortical fast-spiking parvalbumin interneurons enwrapped in the perineuronal net express the metallopeptidase Adamts8, Adams15 and Neprilysin. Mol Psychiatry 2015; 20: 154–161.
11. Do KQ, Cuenod M, Hensch TK. Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophren Bull 2015; 41: 835–846.
12. Yanagi M, Joho RH, Southcott SA, Shukla AA, Ghose S, Tamminga CA. Kv3.1-containing K channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Mol Psychiatry 2014; 19: 573–579.
13. Mauney SA, Athanas KM, Pantazopoulos H, Shaskan N, Passeri E, Berretta S et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol Psychiatry 2013; 74: 427–435.
14. Bernard C, Prochiantz A. Otx2-PNN interaction to regulate cortical plasticity. Neural Plast 2016; 2016: 7931693.
15. Kwok JC, Dick G, Wang D, Fawcett JW. Extracellular matrix and perineuronal nets in CNS repair. Dev Neurobiol 2011; 71: 1073–1089.
16. Cubangchal JH, Steullet P, Morishita H, Kraftsk R, Cuenod M, Hensch TK et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Natl Acad Sci USA 2013; 110: 9130–9135.
17. Gandal MJ, Nesbitt AM, McCurdy RM, Alter MD. Measuring the maturity of the fast-spiking interneuron transcriptional program in autism, schizophrenia, and bipolar disorder. PLoS One 2012; 7: e41215.

Molecular Psychiatry (2017), 936 – 943
Oxidative stress in PVI as mechanism in SZ models

P Steullet et al.
Oxidative stress in PVI as mechanism in SZ models

P Steullet et al.